secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2021-08-03T23:59:59+00:00
Accession:  0001171843-21-005448
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst Chief Business Officer Megan Sniecinski Departs
--------------------------------------------------------

- Megan Sniecinski, Chief Business Officer, separated from BioCryst on July 28, 2021.
- No successor announced as of the filing date.
- Reason for departure not specified in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184321005448/0001171843-21-005448-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184321005448/f8k_080321.htm
  HTML page:      https://secwatch.observer/filing/0001171843-21-005448

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer